Search
Viatris Inc
VTRSAdd to Watchlist
15.750USD
+0.370+2.41%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
18.34BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.41%
5 Days
-1.81%
1 Month
-5.41%
6 Months
+31.03%
Year to Date
+26.51%
1 Year
+77.97%
Key Figures
15.320Open
15.798High
8.81MVolume
LossP/E TTM
5.90P/E Dynamic
0.480Dividend TTM
0.76%Turnover Ratio
15.380Prev. Close
15.220Low
99.33MTurnover
LossP/E Static
1.25P/B
3.05%Div Yield TTM
-0.79%ROA
17.53052wk High
0.71Volume Ratio
-634.20MNet Profit
1.16BShares
-0.2986EPS TTM
0.89Beta
-1.96%ROE
8.40052wk Low
3.76%Amplitude
39.18%Gross Margin
18.34BMarket Cap
-4.20Reward/Risk
1.82%Risk Rate
TradingKey Stock Score of Viatris Inc
Currency: USD Updated: 2026-06-22Key Insights
Viatris Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.45.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Viatris Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Viatris Inc Highlights
StrengthsRisks
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Undervalued
The company’s latest PE is -51.51, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.01B shares, decreasing 6.51% quarter-over-quarter.
Held by Francisco Garcia Parames
Star Investor Francisco Garcia Parames holds 4.71M shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
17.446
Target Price
+13.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Viatris Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Viatris Inc Info
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Ticker SymbolVTRS
CompanyViatris Inc
CEOSmith (Scott A)
Websitehttps://www.viatris.com/en
Related Instruments
+0.54%
+3.37%
+2.60%
+2.07%
+3.54%
+2.98%
+0.66%
+3.33%
+0.14%
-1.44%
+0.32%
+1.53%
+2.59%
-0.36%
+2.58%
0.00%
+0.90%
+2.77%
-5.50%
+2.33%Popular Instruments
72.789
-0.156 (-0.21%)
294.300
-2.710 (-0.91%)
200.040
-8.610 (-4.13%)
4103.570
-7.180 (-0.17%)
670.750
-61.870 (-8.45%)
1961.070
-312.660 (-13.75%)
1051.770
-159.610 (-13.18%)
346.130
-3.550 (-1.02%)
62875.600
+434.900 (+0.70%)
381.610
-23.440 (-5.79%)
FAQs
What is the current price of Viatris Inc (VTRS)?
The current price of Viatris Inc (VTRS) is 15.75.
What is the symbol of Viatris Inc?
The ticker symbol of Viatris Inc is VTRS.
What is the 52-week high of Viatris Inc?
The 52-week high of Viatris Inc is 17.53.
What is the 52-week low of Viatris Inc?
The 52-week low of Viatris Inc is 8.40.
What is the market capitalization of Viatris Inc?
The market capitalization of Viatris Inc is 18.34B.
Is Viatris Inc (VTRS) currently rated as Buy, Hold, or Sell?
According to analysts, Viatris Inc (VTRS) has an overall rating of Buy, with a price target of 17.45.
What is the Earnings Per Share (EPS TTM) of Viatris Inc (VTRS)?
The Earnings Per Share (EPS TTM) of Viatris Inc (VTRS) is -3.00.
